Skip to main content
All lobbying filings

CHAMBER HILL STRATEGIES

Lobbying for SANFORD HEALTH · health system

 Filing 3rd Quarter - Report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 17, 2025
Income
$80,000.00
What the client paid this registrant for the period.
Client based in
South Dakota

Official filing document

 Lobbyists on this filing 5
  • JENNIFER BELL
    Previously held: Health Policy Advisor, Sen. Finance Committee
  • SHAWN FRIESEN
    Previously held: Legislative Director, Rep. Mac Collins (GA-08); Legislative Assistant, Rep. Tom Ewing (IL-15); Clerk, House Judiciary Committee
  • STACEY RAMPY
    Previously held: Legislative Director, Rep. Anna Eshoo (CA-15); Legislative Assistant, Sen. Robert Torricelli (D-NJ); Legislative Assistant, Sen. Barbara Boxer (D-CA)
  • ZACHARY SCHULZ
    Previously held: Legislative Correspondent, Sen. Charles Grassley (R-IA)
  • JENNIFER HOLLAND
    Previously held: Scheduler, Rep. Mary Kaptur (OH-09); Operations Director, Rep. Donald Norcross (NJ-01); Scheduler, Rep. Debbie Dingell (MI-06)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
  • HR 1585
    Conrad State 30 and Physician Access Reauthorization Act
  • HR 3152
    Patent Eligibility Restoration Act of 2025
 Lobbying activity 3
Medicare/Medicaid

policies affecting hospitals and health systems in PL 119-21, the One Big Beautiful Bill Act; various Presidential executive orders; Medicaid minimum nurse staffing ratio rule; CMS-1828-P regarding the payment and regulation of home health agencies

Immigration

S 709/HR 1585, the Conrad State 30 and Physician Access Reauthorization Act

Medical/Disease Research/Clinical Labs

Issues impacting diagnostics including FDA regulation of laboratory developed tests; S 1546/HR 3152, the Patent Eligibility Restoration Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem